

WEDNESDAY 20th NOVEMBER 2013 COMMENCING 09.30 AM

(UNTIL 4.00 PM APPROX)

AT CARDIFF METROPOLITAN UNIVERSITY,

CYNCOED CAMPUS, CYNCOED ROAD, CARDIFF CF23 6XD

AGENDA

- | | | |
|-----|---|-----------------------------------|
| | | Enclosure |
| 1. | Welcome and introduction | |
| 2. | Apologies | |
| 3. | Declarations of interest | |
| 4. | Chairman's Report (verbal update) | |
| 5. | Minutes of previous meeting | 1/AWMSG/1113 |
| 6. | Tramadol Educational Resource Pack | 2/AWMSG/1113 |
| 7. | Appraisal 1: Full Submission
Botulinum toxin type A (Botox[®]) for the management of urinary incontinence in adult patients with neurogenic detrusor overactivity due to subcervical spinal cord injury (traumatic or non-traumatic) or multiple sclerosis, who are not adequately managed with anticholinergics; patients should be already catheterising or willing and able to catheterise if required | 3/AWMSG/1113
Appendices |
| 8. | Appraisal 2: Full Submission
Lixisenatide (Lyxumia[®]) for the treatment of adults with type 2 diabetes mellitus to achieve glycaemic control in combination with oral glucose-lowering medicinal products and/or basal insulin when these, together with diet and exercise, do not provide adequate glycaemic control | 4/AWMSG/1113
Appendices |
| 9. | Proposals to address the implications to NHS Wales of the Cancer Drugs Fund in England | 5/AWMSG/1113 |
| 10. | Appraisal 3: Limited Submission
Etravirine (Intelence[®]) in combination with a boosted protease inhibitor and other antiretroviral medicinal products, for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-experienced paediatric patients from 6 years to less than 18 years of age | 6/AWMSG/1113
Appendices |

- | | | |
|-----|---|-----------------------------------|
| 11. | Appraisal 4: Limited Submission
Saxagliptin (Onglyza®) in adult patients aged 18 years and older with type 2 diabetes mellitus to improve glycaemic control as triple oral therapy in combination with metformin plus a sulphonylurea when this regimen alone, with diet and exercise, does not provide adequate glycaemic control | 7/AWMSG/1113
Appendices |
| 12. | Appraisal 5: Limited Submission
Sodium phenylbutyrate (Pheburane®) for adjunctive therapy in the chronic management of urea cycle disorders, involving deficiencies of carbamylphosphate synthetase, ornithine transcarbamylase or argininosuccinate synthetase. It is indicated in all patients with neonatal-onset presentation (complete enzyme deficiencies, presenting within the first 28 days of life). It is also indicated in patients with late-onset disease (partial enzyme deficiencies, presenting after the first month of life) who have a history of hyperammonaemic encephalopathy | 8/AWMSG/1113
Appendices |
| 13. | Appraisal 6: Limited Submission
Etanercept (Enbrel®) for the treatment of polyarthritis (rheumatoid factor positive or negative) from 2-4 years of age and extended oligoarthritis in children and adolescents from the age of 2 years who have had an inadequate response to, or who have proved intolerant of, methotrexate. Treatment of psoriatic arthritis in adolescents from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, methotrexate. Treatment of enthesitis-related arthritis in adolescents from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, conventional therapy | 9/AWMSG/1113
Appendices |
| 14. | Proposal to adopt NICE commissioning advice on Highly Specialised Technologies within NHS Wales | 10/AWMSG/1113 |
| 15. | Proposal to adopt the principles of Value Based Assessment developed by NICE | 11/AWMSG/1113 |
| 16. | Written evidence request by the National Assembly for Wales's Health and Social Care Committee - medical technologies | 12/AWMSG/1113 |
| 17. | AWMSG Constitution update (for information) | 13/AWMSG/1113 |
| 18. | Date of next meeting:
Wednesday 15th December in Abergavenny | |